Another feature differentiating gelsolin amyloidosis from other protein misfolding diseases is that the amyloidogenic AGelD187N monomer does not have any physiological role in the body, making it a suitable therapeutic target for neutralization. This evidence concerns the gene GSN and proteostasis deficiencies.